Partner With Us NRI

Glaxosmithkline Pharmaceuticals Ltd share Price Today

Company details

6M Return 21.61%
1Y Return 27.16%
Mkt Cap.(Cr) 28,610.13
Volume 161,953
Div Yield 1.90%
OI Chg %
Volume 161,953

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

GlaxoSmithKline Pharmaceuticals announced Q2FY24 & H1FY24 results:

  • Q2FY24:
    • Revenue from operations: Rs 953 crore, with a 5% YoY growth.
    • PBT: Rs 297 crore, showing a solid 13% YoY increase.
    • EBITDA margins: 30.1%.
  • H1FY24:
    • Revenue from operations: Rs 1,691 crore, recording a 3% YoY growth.
    • PBT: Rs 458 crore, improved by 9% YoY.
    • EBITDA margins: 25.3%.

Commenting on the results, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals, said, "Our Q2 performance reflects an overall recovery with market share gains in several key promoted brands across all business units. We held leadership positions for our key brands in relevant therapy areas such as anti-infectives and dermatology.

Our focus in the coming quarters will remain on strong volume-led performance in General Medicines and Pediatric vaccines. We will also explore innovative solutions using Omnichannel strategy to expand our reach and coverage to our target segments. We continue to drive the expansion of the adult immunisation category with Shingrix (Zoster Vaccine Recombinant, Adjuvanted).”



Result PDF

View Other Company Results


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Glaxosmithkline Pharmaceuticals Ltd Stocks COMPARISION


Equity Capital: 1,741.28 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 21,593.44 39,409.91
LAST 3M 57,905.00 19,139.45
LAST 6M 99,888.55 93,017.93
LAST 12M 166,353.23 137,771.51

Glaxosmithkline Pharmaceuticals Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • GlaxoSmithKline Pharmaceuticals Ltd is in the Pharmaceuticals sector is having a market capitalization worth Rs. 25,676.02 crores, it is incorporated in the year 1924. It has reported consolidated sales of Rs. 789.99 crores in June 2021. The company is listed on the Bombay Stock Exchange (BSE) with the code 500660, and also listed on the National Stock Exchange (NSE) with the code GLAXO.

    GlaxoSmithKline Pharmaceuticals is one of the leading manufacturers of pharmaceuticals and vaccines in India. GSK entered the Indian market under the name of H J Foster & Co Ltd. The company generated 76% of its revenue from the selling and distribution of pharmaceuticals while the vaccine segment generated 24% of its revenue. 5 of the brands marketed by GSK feature in the India Pharmaceutical Market. These brands are (i) Augmentin, (ii) Betnovate, (iii) Calpol, (iv) Ceftum, and (v) Synflorix. GSK has a developed a team of over 5,000 employees spread across the country. GSK has also established two global Research & Development centers in the country. The promoters of the company own 75.0% of the stake in the company, Foreign Institutional Investors (FII) own 1.61% of the stake, Domestic Institutional Investors (DII) own 10.92%, and others (such as public & retail investors) hold the balance of 12.47%.

    In June 2021, quarterly net revenue was Rs. 773.46 crores, which has increased by approximately 19.24 % from Rs. 648.65 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 120.4 crores, which has improved sharply and increased by nearly 8.51% from a net profit of Rs. 110.96 crores in June 2020. In June 2021, the reported operating profit was at Rs. 645.05 crores, which is increased by 10.95% as compared to an operating profit of Rs. 581.39 crores for the quarter ending in June 2020. From an EPS of Rs. 6.55 in June 2020, the EPS of Glaxosmithkline Pharmaceuticals Ltd has improved and reached an EPS of Rs. 7.11 per share in June 2021. GLAXO's stock closed at Rs. 1,515.65 on 27th August’2021 (NSE). GlaxoSmithKline Pharmaceuticals Ltd has returned 3.77% in the last six months and returned 5.18% negatively in the previous year.

Registered Address

GSK House, Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030

Tel : 91-022-24959595
Email : askus:gsk.com
Website : http://www.gsk-india.com

Karvy Computershare Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 500660
Book Closure Date (Month) :
BSE Group : A
ISIN : INE159A01016

FAQ’s on Glaxosmithkline Pharmaceuticals Ltd Shares

You can buy Glaxosmithkline Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Glaxosmithkline Pharmaceuticals Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Dec 07, 2023 03:55 PM the closing price of Glaxosmithkline Pharmaceuticals Ltd was ₹ 1,688.85.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Dec 07, 2023 03:55 PM, the market cap of Glaxosmithkline Pharmaceuticals Ltd stood at ₹ 28,610.13.

The latest PE ratio of Glaxosmithkline Pharmaceuticals Ltd as of Dec 07, 2023 03:55 PM is 44.99

The latest PB ratio of Glaxosmithkline Pharmaceuticals Ltd as of Dec 07, 2023 03:55 PM is 0.05

The 52-week high of Glaxosmithkline Pharmaceuticals Ltd is ₹ 1,739.75 while the 52-week low is ₹ 1,227.00

Download Our App

market app
market app